A new AMR Innovation Programme launched at Global Health today (30 October), opened by Professor Steve Field, UK Special Healthcare Representative to Saudi Arabia. Professor Field raised the need for new health technologies to meet the UK government’s priority to contain and control antimicrobial resistance (AMR) by 2040.
The new programme targeting AMR, led by Healthcare Innovation Consortium in collaboration with Mecomed and Barts Life Sciences, is targeting healthtech innovators in the UK, Ireland and Middle East with solutions that can directly address AMR or be adapted to do so.
AMR occurs when the microorganisms which cause disease are no longer affected by antimicrobial medicines. AMR is accelerated by inappropriate use of antimicrobial drugs, poor infection prevention and control practices, and a lack of new antimicrobial drugs being developed.
The goal is to fast-track cutting-edge technologies into the market, with a special focus on the UK and the Middle East, to promote the optimal use of antibiotics in clinical practice, enhance infection prevention and control, and aid in the identification of antibiotic-resistant bacteria.
Professor Steve Field, UK Special Healthcare Representative to Saudi Arabia, said:
“AMR is one of the biggest threats to our health across the world and relies on a coordinated, multi-nation and sector effort to tackle it.
“The HIC’s AMR Innovation Programme aligns with the UK Government’s national action plan to control AMR by preventing infections, ensuring timely diagnosis, and driving the appropriate use of antimicrobials.”
Suzie Ali-Hassan, Chief Partnerships Officer, Healthcare Innovation Consortium: said:
“If we don’t address AMR, everyday operations like caesarean sections and hip replacements would be too dangerous to perform, and minor illnesses could become life-threatening. We want to amplify the UK’s contribution to containing and controlling AMR by bringing innovators together with researchers and industry experts to tackle this global priority.
“We’re looking for diagnostic tools, smart systems, prescribing tools, screening devices, and other technologies that can support AMR prevention and management.”
The programme will also feature support from leading law firm, Hill Dickinson, and commercialisation specialists, Piper Health, and will support up to six successful applicants with:
- In-depth insights into the NHS and Middle East markets
- Engagement with academic and clinical experts in the field
- Expert advice on regulation and compliance in both markets
- Facilitated connections on a national and international level
- Support to secure investment where applicable.